Veerbhan kesarwani

Mr. Veerbhan kesarwani

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
ARAkanksha Roberts
Akanksha Roberts
Raghuraj ChouhanRaghuraj Chouhan
Raghuraj Chouhan
DSDeepshikha Shahdeo
Deepshikha Shahdeo
NSNarlawar Sagar Shrikrishna
Narlawar Sagar Shrikrishna
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
Sonu GandhiSonu Gandhi
Sonu Gandhi
Coronavirus disease 2019 (COVID-19), which started out as an outbreak of pneumonia, has now turned into a pandemic due to its rapid transmission. Besides developing a vaccine, rapid, accurate, and cost-effective diagnosis is essential for monitoring and combating the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its related variants on time with precision and accuracy. Currently, the gold standard for detection of SARS-CoV-2 is Reverse Transcription Polymerase Chain Reaction (RT-PCR), but it lacks accuracy, is time-consuming and cumbersome, and fails to detect multi-variant forms of the virus. Herein, we have summarized conventional diagnostic methods such as Chest-CT (Computed Tomography), RT-PCR, Loop Mediated Isothermal Amplification (LAMP), Reverse Transcription-LAMP (RT-LAMP), as well new modern diagnostics such as CRISPR–Cas-based assays, Surface Enhanced Raman Spectroscopy (SERS), Lateral Flow Assays (LFA), Graphene-Field Effect Transistor (GraFET), electrochemical sensors, immunosensors, antisense oligonucleotides (ASOs)-based assays, and microarrays for SARS-CoV-2 detection. This review will also provide an insight into an ongoing research and the possibility of developing more economical tools to tackle the COVID-19 pandemic.

1 August 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
DSDeepshikha Shahdeo
Deepshikha Shahdeo
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
DSDeepa Suhag
Deepa Suhag
JAJahangeer Ahmed
Jahangeer Ahmed
SASaad M. Alshehri
Saad M. Alshehri
Sonu GandhiSonu Gandhi
Sonu Gandhi

1 February 2022 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ARAkanksha Roberts
Akanksha Roberts
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
RGRupal Gupta
Rupal Gupta
Sonu GandhiSonu Gandhi
Sonu Gandhi

11 February 2022 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
DSDeepshikha Shahdeo
Deepshikha Shahdeo
ARAkanksha Roberts
Akanksha Roberts
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
MHMilena Horvat
Milena Horvat
Raghuraj ChouhanRaghuraj Chouhan
Raghuraj Chouhan
Sonu GandhiSonu Gandhi
Sonu Gandhi
Compared with other nanomaterials, surface-modified iron oxide nanoparticles (IONPs) have gained attraction for cancer therapy applications due to its low toxicity, and long retention time. An innocuous targeting strategy was developed by generation of fluorescein isothiocyanate (FITC)-labeled peptide (growth factor domain (GFD) and somatomedin B domain (SMB)) functionalized, chitosan-coated IONPs (IONPs/C). It can be used to target urokinase plasminogen activator receptor (uPAR), which is a surface biomarker, in ovarian cancer. Binding affinity between uPAR and peptides (GFD and SMB) were revealed by in-silico docking studies. The biophysical characterizations of IONPs, IONPs/C, and IONPs/C/GFD-FITC or SMB-FITC nanoprobes were assessed via Vibrating Sample Magnetometer (VSM), Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), and Fourier Transform Infrared Spectroscopy (FT-IR). Prussian Blue staining, fluorescence spectroscopy, and fluorescence imaging were performed to confirm the targeting of nanoprobes with the surface receptor uPAR. The combination of IONPs/C/GFD+SMB showed efficient targeting of uPAR in the tumor microenvironment, and thus can be implemented as a molecular magnetic nanoprobe for cancer cell imaging and targeting.

23 May 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
SGSagar Gupta
Sagar Gupta
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
UBUmesh Bhati
Umesh Bhati
JYJyoti
Jyoti
RSRavi Shankar
Ravi Shankar
Unlike animals, variability in transcription factors (TFs) and their binding regions (TFBRs) across the plants species is a major problem that most of the existing TFBR finding software fail to tackle, rendering them hardly of any use. This limitation has resulted into underdevelopment of plant regulatory research and rampant use of Arabidopsis-like model species, generating misleading results. Here, we report a revolutionary transformers-based deep-learning approach, PTFSpot, which learns from TF structures and their binding regions’ co-variability to bring a universal TF-DNA interaction model to detect TFBR with complete freedom from TF and species-specific models’ limitations. During a series of extensive benchmarking studies over multiple experimentally validated data, it not only outperformed the existing software by >30% lead but also delivered consistently >90% accuracy even for those species and TF families that were never encountered during the model-building process. PTFSpot makes it possible now to accurately annotate TFBRs across any plant genome even in the total lack of any TF information, completely free from the bottlenecks of species and TF-specific models.

24 September 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
RGRupal Gupta
Rupal Gupta
RVRamesh Vetukuri
Ramesh Vetukuri
SKSandeep Kumar Kushwaha
Sandeep Kumar Kushwaha
Sonu GandhiSonu Gandhi
Sonu Gandhi
Ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strains is posing new COVID-19 diagnosis and treatment challenges. To help efforts to meet these challenges we examined data acquired from proteomic analyses of human SARS-CoV-2-infected cell lines and samples from COVID-19 patients. Initially, 129 unique peptides were identified, which were rigorously evaluated for repeats, disorders, polymorphisms, antigenicity, immunogenicity, toxicity, allergens, sequence similarity to human proteins, and contributions from other potential cross-reacting pathogenic species or the human saliva microbiome. We also screened SARS-CoV-2-infected NBHE and A549 cell lines for presence of antigenic peptides, and identified paratope peptides from crystal structures of SARS-CoV-2 antigen-antibody complexes. We then selected four antigen peptides for docking with known viral unbound T-cell receptor (TCR), class I and II peptide major histocompatibility complex (pMHC), and identified paratope sequences. We also tested the paratope binding affinity of SARS-CoV T- and B-cell peptides that had been previously experimentally validated. The resultant antigenic peptides have high potential for generating SARS-CoV-2-specific antibodies, and the paratope peptides can be directly used to develop a COVID-19 diagnostics assay. The presented genomics and proteomics-based in-silico approaches have apparent utility for identifying new diagnostic peptides that could be used to fight SARS-CoV-2.